Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide
A three-ingredient combination tablet used to treat high blood pressure (hypertension) in adults whose blood pressure is not controlled on fewer medications.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 15 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
How we combine label and product data →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
This medicine can cause serious harm or death to an unborn baby. If you find out you are pregnant at any point while taking this medicine, stop taking it right away and call your doctor immediately. The ingredients in this tablet act on a system in the body called the renin-angiotensin system. When used during the second or third trimester of pregnancy, drugs that affect this system can reduce the baby's kidney function, cause dangerously low amniotic fluid levels, and lead to birth defects or death. There are no specific warning signs to watch for — which is why stopping the medicine as soon as pregnancy is confirmed is so important.
Patient information guide — a plain-language walkthrough of Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide, written from its FDA label.
What Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is used for
▾
Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide is a three-ingredient oral tablet used to lower blood pressure in adults.
- Treats high blood pressure (hypertension), alone or alongside other blood pressure medicines
- Lowers blood pressure to reduce the risk of stroke and heart attack
- Tribenzor is indicated for hypertension when blood pressure is not controlled on fewer medicines
- Not indicated as initial (first-ever) therapy for high blood pressure — this combination is used after simpler regimens have been tried
How Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide works
▾
This tablet targets three separate pathways that control blood pressure. Olmesartan blocks angiotensin II — a hormone that normally tightens blood vessels and causes the body to hold onto sodium — from binding to its receptor (called the AT1 receptor) in blood vessel walls. Amlodipine prevents calcium from entering vascular muscle cells, which allows blood vessels to relax and widen. Hydrochlorothiazide acts in the kidneys to flush out extra sodium and water, shrinking the volume of fluid the heart must pump. Because each ingredient works at a different site, the combination lowers blood pressure more effectively than any single ingredient alone.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide dosage
▾
These tablets are taken once daily by mouth and can be taken with or without food. Your prescriber will personalize your dose based on how you responded to previous blood pressure medicines. Dose changes, if needed, are typically made no more often than every two weeks.
- Take at the same time each day to keep blood pressure steady
- If you miss a dose, take it as soon as you remember — but skip it if it is almost time for your next dose; never double up
- Do not stop taking this medicine without talking to your doctor first
Dosing details from the FDA-approved label
From the Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Hypertension (olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets)
- Dose once daily
- Dosage may be increased after 2 weeks (label also states in 2 week intervals, as needed)
- Maximum: 40 mg/10 mg/25 mg once daily
- Dose selection should be individualized based on previous therapy.
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Dose once daily. Dosage may be increased in 2 week intervals, as needed. The maximum recommended dose of olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets is 40 mg/10 mg/25 mg. Dose selection should be individualized based on previous therapy. • Dose once daily. Dosage may be increased after 2 weeks to a maximum dose of 40 mg/10 mg/25 mg once daily ( 2 ). • Dose selection should be individualized based on previous therapy ( 2 ).
Read the full Dosage and Administration section on DailyMed →
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide side effects
▾
Common side effects
- Dizziness
- Swelling in the hands, feet, or ankles (peripheral edema)
- Headache
- Fatigue or tiredness
- Nausea
- Muscle cramps or spasms
- Diarrhea
- Stuffy or runny nose (nasopharyngitis)
When to get medical help
- Call your doctor right away if you become pregnant — this medicine must be stopped as soon as possible during pregnancy
- Get medical help if you feel faint, very lightheaded, or lose consciousness (possible low blood pressure)
- Call your doctor if you notice a significant decrease in how much urine you produce — this could signal kidney problems
- Seek emergency care if you develop sudden eye pain, blurred vision, or see halos — this may be acute angle-closure glaucoma
- Tell your doctor if you develop severe, persistent diarrhea with significant weight loss — this can be a rare gut reaction to olmesartan
- Get help immediately if you develop chest pain that is new or worsening, especially if you have heart disease
- Contact your doctor if you notice muscle weakness, irregular heartbeat, or unusual tiredness — these can be signs of electrolyte imbalance
The most common side effects reported in clinical trials include:
- Dizziness (most common reason people stop this medicine)
- Swelling in the feet or ankles (peripheral edema)
- Headache
- Fatigue
- Nausea
- Muscle spasms or cramps
- Diarrhea
- Stuffy nose or cold symptoms (nasopharyngitis)
More serious reactions to act on immediately include fainting, sudden chest pain, significant decrease in urination, sudden eye pain or vision loss, and severe ongoing diarrhea with weight loss — contact your doctor or get emergency help if any of these occur.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide warnings and precautions
▾
- Fetal toxicity (pregnancy risk): This medicine can cause serious kidney damage and death in an unborn baby. Stop it immediately if you become pregnant and call your doctor.
- Low blood pressure (hypotension): Especially likely if you are dehydrated, on a low-salt diet, or already taking diuretics. Dizziness or fainting when standing are warning signs.
- Kidney function: This combination can worsen kidney function in some people, particularly those with existing kidney disease or severe heart failure. Kidney labs should be monitored.
- Electrolyte imbalances: The hydrochlorothiazide component can lower potassium, sodium, and magnesium levels. The olmesartan component can raise potassium. Watch for muscle weakness, cramps, or irregular heartbeat.
- Sprue-like enteropathy: Severe chronic diarrhea and significant weight loss have been reported with olmesartan, sometimes starting months or years after beginning the drug. Tell your doctor if this develops.
- Acute angle-closure glaucoma: A rare but sudden eye emergency — eye pain, blurred vision, or redness — can occur with the hydrochlorothiazide component. Seek care immediately.
- Worsening angina or heart attack: People with severe coronary artery disease may experience increased chest pain or a heart attack when starting amlodipine or increasing its dose.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide interactions
▾
Several medicines, foods, and substances can interact with this combination tablet — tell your prescriber and pharmacist about everything you take:
- NSAIDs (ibuprofen, naproxen, celecoxib) — can blunt blood pressure control and increase the risk of kidney damage, especially in older adults or those with kidney disease
- Aliskiren (Tekturna) — must not be combined in patients with diabetes; should be avoided in patients with kidney disease
- ACE inhibitors or other ARBs — combining multiple drugs that act on the renin-angiotensin system raises the risk of low blood pressure, high potassium, and kidney failure
- Lithium — olmesartan can cause lithium to build up to toxic levels in the blood
- Simvastatin — limit the daily dose of simvastatin when taken with amlodipine to avoid muscle side effects
- Cyclosporine or tacrolimus — amlodipine can raise blood levels of these immunosuppressants
- CYP3A inhibitors (certain antifungals, antibiotics, and others) — can increase amlodipine exposure in the body
- Alcohol, sedatives, or narcotic pain medicines — can worsen dizziness or low blood pressure, especially upon standing
- Antidiabetic medicines — hydrochlorothiazide can affect blood sugar; dose adjustment of diabetes medicines may be needed
- Cholestyramine or colestipol (cholesterol binders) — can reduce the absorption of hydrochlorothiazide; timing of doses matters
Interactions listed in the FDA-approved label
From the Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors: In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration may result in deterioration of renal function, including possible acute renal failure, and the antihypertensive effect may be attenuated. Monitor renal function periodically in patients receiving olmesartan medoxomil and NSAID therapy.
- Dual inhibition of the renin-angiotensin system (ARBs, ACE inhibitors, aliskiren): Associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes. Do not co-administer aliskiren in patients with diabetes.
- Colesevelam hydrochloride: Interaction with olmesartan is noted in the label summary. Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose.
- Lithium: Increases in serum lithium concentrations and lithium toxicity.
- Simvastatin (amlodipine): Interaction when coadministered with amlodipine. Limit simvastatin to 20 mg daily when coadministered.
- Cyclosporin and tacrolimus (amlodipine): Increased exposure to cyclosporin and tacrolimus.
- CYP3A inhibitors (amlodipine): Increased amlodipine exposure when coadministered with CYP3A inhibitors.
- Antidiabetic drugs (hydrochlorothiazide): Dosage adjustment of antidiabetic may be required. Dosage adjustment of antidiabetic may be required.
- Cholestyramine and colestipol (hydrochlorothiazide): Reduced absorption of thiazides.
- NSAIDs (hydrochlorothiazide): Can reduce the diuretic, natriuretic, and antihypertensive effects of diuretics.
Read the label’s full interactions text
7 DRUG INTERACTIONS Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. • Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. • Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose. • Lithium: Increases in serum lithium concentrations and lithium toxicity. Amlodipine ( 7.2 ): • Limit simvastatin to 20 mg daily when coadministered. • Increased exposure to cyclosporin and tacrolimus • Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. • Cholestyramine and colestipol: Reduced absorption of thiazides. • NSAIDs: Can reduce the diuretic, natriuretic, and antihypertensive effects of diuretics. 7.1 Drug Interactions with Olmesartan Medoxomil Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including olmesartan medoxomil, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving olmesartan medoxomil and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide
▾
- Pregnancy: Do not use this medicine if you are pregnant. If you become pregnant while taking it, stop immediately and call your doctor.
- Breastfeeding: Breastfeeding is not recommended while taking this medicine.
- Severe kidney disease: Avoid this combination if your creatinine clearance is 30 mL/min or less.
- Severe liver disease: Use with caution — amlodipine is processed by the liver and stays in the body much longer when liver function is impaired. A lower starting amlodipine dose (2.5 mg) is recommended for severe hepatic impairment, but that dose is not available in this combination tablet.
- Dehydration or low-salt diet: Correct fluid or salt deficits before starting — you may be at high risk for a dangerous drop in blood pressure.
- Diabetes: This medicine should not be combined with aliskiren if you have diabetes. Also, hydrochlorothiazide can raise blood sugar.
- Sulfonamide or penicillin allergy: May increase the risk of the rare eye reaction (acute angle-closure glaucoma) from the hydrochlorothiazide component.
- Severe aortic stenosis or coronary artery disease: Use with caution — amlodipine may worsen angina in some patients with these conditions.
- Older adults (75+): The recommended starting dose of amlodipine for patients 75 and older (2.5 mg) is not available in this fixed-dose combination tablet — discuss this with your prescriber.
- Children: Safety and effectiveness have not been established in pediatric patients.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide overdose
▾
Taking too much of this combination tablet could cause a dangerous drop in blood pressure, dizziness, fainting, or a rapid or slow heart rate. With the amlodipine component specifically, severe overdose can cause marked low blood pressure and reflex fast heart rate. With the hydrochlorothiazide component, overdose can cause dehydration and electrolyte loss (especially low potassium and sodium). If you suspect an overdose, call 911 or Poison Control immediately and seek emergency care — do not try to manage this at home.
What Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide does in the body
▾
All three ingredients work together to lower both sitting and standing blood pressure without causing a significant increase in heart rate during chronic use. Amlodipine's blood pressure-lowering effect is sustained for at least 24 hours after a once-daily dose, and its effect is greater in people with higher pre-treatment blood pressure levels. Hydrochlorothiazide begins producing a diuretic effect within about 2 hours of an oral dose, peaking around 4 hours and lasting 6 to 12 hours. Together, the three components complement each other — the olmesartan component also tends to offset the potassium loss that hydrochlorothiazide would otherwise cause.
How your body processes Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide
▾
After swallowing a tablet, peak blood levels of olmesartan are reached in about 1.5 to 3 hours, amlodipine in 6 to 8 hours, and hydrochlorothiazide in 1.5 to 2 hours. Food does not affect how much of any of the three ingredients is absorbed. Amlodipine is heavily processed by the liver and has a very long half-life of roughly 30 to 50 hours, meaning it stays in the body for days — steady-state levels build up after about 7 to 8 days of daily dosing. Olmesartan is eliminated partly through the kidneys and partly through the bile, while hydrochlorothiazide is cleared almost entirely by the kidneys unchanged. Kidney or liver impairment can significantly increase how much of these drugs accumulate in the body.
How to store Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide
▾
Stored at 20° to 25°C (68° to 77°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide — the kind of thing our pharmacy team would talk through with you at the counter.
Why am I taking three medicines in one pill? Is that normal?
▾
Can I take this medicine if I'm pregnant or trying to get pregnant?
▾
I've been feeling dizzy since I started this. Should I be worried?
▾
Are there any common medicines I should avoid while taking this?
▾
What warning signs should make me call my doctor right away?
▾
Does it matter what time of day I take this, or whether I take it with food?
▾
Is Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide available over the counter?
▾
When was Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide first available?
▾
Who makes Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide on HelloPharmacist
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide forms and strengths (how it comes)
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide) tablets are indicated to treat high blood pressure (hypertension), alone or with other blood pressure medicines
- Olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets are not intended as the first medicine used to start blood pressure treatment
- Take olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets once daily by mouth, with or without food
- Tribenzor and other olmesartan medoxomil / amlodipine / hydrochlorothiazide tablets may be dose-adjusted by your prescriber in two-week intervals as needed
- Swallow the tablet whole and follow your prescriber's exact dose instructions — do not adjust your dose on your own
Show 4 more strengths Show fewer strengths
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide on the U.S. market: products, makers and brands
How Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
12 companies list 86 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2016. Brand names on the directory include Tribenzor; the rest are generics.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is used (Medicaid data)
A general measure of how commonly Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide prescribed? Of the 1,599 medications we measure, Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide ranks #905 by Medicaid prescriptions — more than 43% of them.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 15 of 111 listed Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide NDCs with Medicaid activity.
Compare Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide products
A representative set of FDA-listed product records for Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 5; 12.5; 20 mg/1; mg/1; mg | Oral | Bryant Ranch Prepack × 4 listings | ANDA | View NDC → |
| 5; 25; 40 mg/1; mg/1; mg | Oral | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| 10; 12.5; 40 mg/1; mg/1; mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| 5; 12.5; 20 mg/1; mg/1; mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| 5; 12.5; 40 mg/1; mg/1; mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| 5; 25; 40 mg/1; mg/1; mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| 10; 12.5; 40 mg/1; mg/1; mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| 10; 25; 40 mg/1; mg/1; mg | Oral | Cosette Pharmaceuticals, Inc. | NDA | View NDC → |
| 5; 12.5; 20 mg/1; mg/1; mg | Oral | Daiichi Sankyo, Inc. | NDA | View NDC → |
| 5; 12.5; 40 mg/1; mg/1; mg | Oral | Daiichi Sankyo, Inc. | NDA | View NDC → |
| 5; 25; 40 mg/1; mg/1; mg | Oral | Daiichi Sankyo, Inc. | NDA | View NDC → |
| 10; 12.5; 40 mg/1; mg/1; mg | Oral | Daiichi Sankyo, Inc. | NDA | View NDC → |
| 10; 25; 40 mg/1; mg/1; mg | Oral | Daiichi Sankyo, Inc. | NDA | View NDC → |
| 5; 12.5; 20 mg/1; mg/1; mg | Oral | Doh Central Pharmacy | NDA | View NDC → |
| OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Micro Labs Limited | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Micro Labs Limited | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Micro Labs Limited | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Micro Labs Limited | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Micro Labs Limited | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Par Health USA, LLC × 2 listings | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Par Health USA, LLC × 2 listings | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Par Health USA, LLC × 2 listings | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Par Health USA, LLC × 2 listings | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Par Health USA, LLC × 2 listings | ANDA | View NDC → |
| 5; 12.5; 20 mg/1; mg/1; mg | Oral | Par Pharmaceutical, Inc. × 2 listings | ANDA | View NDC → |
| 5; 12.5; 40 mg/1; mg/1; mg | Oral | Par Pharmaceutical, Inc. × 2 listings | ANDA | View NDC → |
| 5; 25; 40 mg/1; mg/1; mg | Oral | Par Pharmaceutical, Inc. × 2 listings | ANDA | View NDC → |
| 10; 12.5; 40 mg/1; mg/1; mg | Oral | Par Pharmaceutical, Inc. × 2 listings | ANDA | View NDC → |
| 10; 25; 40 mg/1; mg/1; mg | Oral | Par Pharmaceutical, Inc. × 2 listings | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 5; 25; 40 mg/1; mg/1; mg | Oral | Remedyrepack Inc. × 2 listings | NDA AUTHORIZED GENERIC | View NDC → |
| OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Slate Run Pharmaceuticals, LLC | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Slate Run Pharmaceuticals, LLC | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Slate Run Pharmaceuticals, LLC | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Slate Run Pharmaceuticals, LLC | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Slate Run Pharmaceuticals, LLC | ANDA | View NDC → |
| 5; 12.5; 20 mg/1; mg/1; mg | Oral | Sun Pharmaceutical Industries, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 5; 12.5; 40 mg/1; mg/1; mg | Oral | Sun Pharmaceutical Industries, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 5; 25; 40 mg/1; mg/1; mg | Oral | Sun Pharmaceutical Industries, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 10; 12.5; 40 mg/1; mg/1; mg | Oral | Sun Pharmaceutical Industries, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 10; 25; 40 mg/1; mg/1; mg | Oral | Sun Pharmaceutical Industries, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 5; 12.5; 20 mg/1; mg/1; mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 5; 12.5; 40 mg/1; mg/1; mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 5; 25; 40 mg/1; mg/1; mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 10; 12.5; 40 mg/1; mg/1; mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 10; 25; 40 mg/1; mg/1; mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
Showing 86 of 86 products — FDA National Drug Code Directory. See every product, package size and price: browse all 86 Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide NDCs →
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide FDA approval history
How Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide recalls since July 2021.
✅No Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide supply and shortage status
Whether Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide brand names
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is sold under one brand name in the FDA directory — Tribenzor. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide: manufacturers and labelers
12 companies list Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Teva Pharmaceuticals USA, Inc., Cosette Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for this Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Doh Central Pharmacy is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →